Biotech | October 27, 2025
Novartis to acquire Avidity Biosciences for $12 billion
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
CRISPR-based detection enables highly specific molecular recognition
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Subscribe To Our Newsletter & Stay Updated
